<DOC>
	<DOC>NCT02920697</DOC>
	<brief_summary>The purpose of this study is to determine the safety profile and tolerability of S 55746 in patients with CLL, B-Cell NHL and MM, in terms of Dose-Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD) and determine the Recommended Phase 2 Dose (RP2D) through safety profile (DLT, MTD), PK profile, PD profile and preliminary efficacy.</brief_summary>
	<brief_title>Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>Women or men aged &gt;/=18 years Patients with a measurable histologically confirmed Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Diffuse Large BCell Lymphoma (DLBCL), Small Lymphocytic Lymphoma (SLL) and Marginal Zone Lymphoma (MZL) (Arm A), or patients with an evaluable immunophenotypically confirmed CLL (Arm B), or patients with a measurable Multiple Myeloma t(11;14) (arm A expansion part) according to International Myeloma Working Group (IMWG) criteria Relapsed after or refractory disease to standard treatments, and require treatment in the opinion of the investigator Estimated life expectancy &gt; 12 weeks World Health Organization (WHO) performance status 02 Adequate bone marrow, renal and hepatic functions, normal coagulation profile No evidence or treatment for another malignancy within 2 years prior to study entry. Curatively treated nonmelanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia is allowed Additional inclusion criteria for food interaction cohort: Bcell NHL patients at low risk of tumour lysis syndrome (TLS) Recent/concomitant treatment altering gastric pH Previous treatment with a BH3 mimetic Previous therapy for the studied disease within 3 weeks before first intake Radioimmunotherapy, radiotherapy within 8 weeks before first intake Major surgery within 3 weeks before first day of study drug dosing Corticosteroids &gt;= 20 mg prednisone equivalent per day within 7 days before first intake Anticoagulant oral drugs, aspirin &gt; 325 mg/day Positive direct antiglobulin test (Coombs test) and haptoglobin below normal value Prior allogenic stem cell transplant Autologous stem cell transplant within 3 months before first intake NHL patients diagnosed with PostTransplant Lymphoproliferative Disease, Burkitt's lymphoma, Burkittlike lymphoma, or lymphoblastic lymphoma/leukaemia Human immunodeficiency virus (HIV) Known acute or chronic hepatitis B or hepatitis C Impaired cardiac function Medications known to prolong corrected QT (QTc) interval History or/ clinically suspicious for cancer related Central Nervous System disease Solitary extramedullary plasmacytoma Laboratory Signs of TLS Strong or moderate CYP3A4 inhibitors/inducers (treatment, food or drink products) Treatment highly metabolized by the CYP3A4 or CYP2D6 and/or substrates with a narrow therapeutic index, multienzyme and/or OATP substrates or herbal products. Known hypersensitivity to rasburicase Glucose6phosphate dehydrogenase (G6PD) deficiency and other cellular metabolic disorders known to cause haemolytic anaemia Patients receiving proton pump inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>